Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as diphenhydramine, which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of terfenadine and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.
In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.
Tanta University, Tanta, Egypt
Tanta University, Tanta, Elgharbia, Egypt
Syneos Health Clinic inc., Quebec, Canada
Q-Pharm, Herston, Queensland, Australia
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
UCLA Medical Center Site Number : 1003, Santa Monica, California, United States
Emory University School of Medicine Site Number : 1005, Atlanta, Georgia, United States
Infusion Associates Site Number : 1001, Grand Rapids, Michigan, United States
ICON Lenexa, Lenexa, Kansas, United States
Investigational Site Number : 1240001, Kingston, Ontario, Canada
BCT Ltd., Dhaka, Ramna, Bangladesh
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.